AKR1C4

AKR1C4 is a virtually liver-specific, NAD(P)(H)-dependent aldo-keto reductase that catalyzes the stereospecific interconversion of ketosteroids and hydroxysteroids at the 3-, 17-, and 20-positions, thereby governing the levels of active sex hormones and dihydrosteroid metabolites (PMID:10998348). It is the most catalytically efficient AKR1C isoform, inactivating 5α-DHT to 3α-androstanediol, oxidizing testosterone, reducing oestrone to 17β-oestradiol, and forming 5α/5β-tetrahydrosteroids (PMID:10998348); it is the major hepatic enzyme of the 5β-pathway, reducing 5β-dihydrotestosterone preferentially to the 3α-hydroxy configuration (PMID:21521174). Its distinctive catalytic behavior derives in part from His-216 (in place of the Tyr conserved in AKR1C1–1C3), which orients the nicotinamide ring of the coenzyme and shapes the substrate-binding cavity, modulating cofactor affinity, substrate-dependent kinetics, and inhibitor sensitivity (PMID:11104674). Hepatic, cell-type-restricted expression is established by cooperative transactivation through HNF-4α/HNF-4γ and HNF-1α binding to adjacent promoter elements—with non-activating vHNF-1-C occupancy explaining silencing in non-hepatic cells—and is further induced by LXRα binding to an upstream response element (PMID:11284743, PMID:12220531, PMID:18024509). Beyond steroid metabolism, AKR1C4 enzymatic activity suppresses ferroptosis to confer chemotherapy resistance in colorectal cancer cells, an effect lost in a catalytically dead mutant (PMID:38890190).

1. 2000 High

   Established that AKR1C4 is a bona fide, highly efficient steroid-metabolizing oxidoreductase, defining its molecular activity and the liver-restricted context in which it operates.

   Evidence Recombinant protein kinetics, product identification, and isoform-specific RT-PCR across AKR1C1–1C4

   PMID:10998348

   Open questions at the time

   • In vitro substrate preferences do not establish the dominant physiological reaction direction in hepatocytes
   • Did not resolve structural basis of catalytic superiority over other isoforms
2. 2000 High

   Pinpointed His-216 as a determinant of AKR1C4's cofactor orientation and substrate cavity, explaining its kinetic distinctiveness from the Tyr-216 paralogs.

   Evidence Site-directed mutagenesis (H216Y, H216F) with kinetic, inhibitor, and activator binding analysis on purified enzymes

   PMID:11104674

   Open questions at the time

   • No crystal structure of AKR1C4 itself; interpretation rests on family member structures
   • Effect of His-216 on the full physiological substrate panel not exhaustively mapped
3. 2001 High

   Resolved how hepatic AKR1C4 transcription is driven, showing cooperative control by adjacent HNF-4α/γ and HNF-1α cis-elements.

   Evidence Luciferase reporters, footprinting, EMSA/supershift, and promoter mutagenesis in HepG2 cells

   PMID:11284743

   Open questions at the time

   • Did not address signals upstream that modulate HNF factor activity
   • Promoter analysis in a single hepatic cell line
4. 2002 Medium

   Explained tissue-restricted expression as differential transcription-factor occupancy, with non-activating vHNF-1-C occupying the same elements in non-hepatic cells.

   Evidence Reporter assays, supershift EMSA, RT-PCR, and vHNF-1-C transfection in HepG2 vs ACHN cells

   PMID:12220531

   Open questions at the time

   • Single-lab extension of the prior promoter study
   • Does not establish in vivo relevance of vHNF-1-C silencing across tissues
5. 2007 Medium

   Added a nuclear-receptor input by showing LXRα directly activates AKR1C4 transcription, linking the gene to lipid/sterol-sensing regulation.

   Evidence HMM prediction of response elements plus ChIP/microarray and protein expression analysis

   PMID:18024509

   Open questions at the time

   • Physiological ligand/condition triggering LXRα-driven induction not defined
   • Two complementary methods from a single lab
6. 2011 High

   Identified AKR1C4 as the principal hepatic enzyme of the 5β-pathway, defining its stereochemical product preference for 5β-dihydrotestosterone.

   Evidence In vitro reconstitution with LC-MS product characterization, kinetics, and molecular docking across AKR1C1–1C4

   PMID:21521174

   Open questions at the time

   • In vivo flux through the 5β-pathway not directly quantified
   • Docking model not validated by experimental structure
7. 2024 Medium

   Extended AKR1C4 function beyond steroid metabolism, demonstrating that its catalytic activity suppresses ferroptosis and drives chemoresistance in colorectal cancer.

   Evidence CRISPR/Cas9 knockout, Y55A catalytic-dead rescue, viability/iron/lipid-peroxidation readouts in chemoresistant cell lines

   PMID:38890190

   Open questions at the time

   • The metabolic substrate/product responsible for ferroptosis suppression is not identified
   • Single-lab cell-line study without in vivo confirmation
   • Mechanism linking enzymatic output to lipid peroxidation unresolved

• It remains unknown how AKR1C4's steroid-reductase chemistry mechanistically connects to lipid-peroxidation/ferroptosis control, and whether its in vivo physiological role is dominated by steroid clearance or by the cancer-associated activity.
• No identified endogenous substrate bridging steroid metabolism and ferroptosis
• No experimentally determined AKR1C4 structure
• In vivo physiological consequences of expression changes not established